Ilana Fogelman

Ilana Fogelman

Auto-generated profile, based on publicly available information

Ilana Fogelman

C2N Diagnostics, LLC, St. Louis, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
MMMark Monane
Mark Monane
KJKim G. Johnson
Kim G. Johnson
BSB. Joy Snider
B. Joy Snider
RTRaymond Scott Turner
Raymond Scott Turner
JDJonathan D. Drake
Jonathan D. Drake
JBJoel Braunstein
Joel Braunstein
Objective: The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.Methods: The Quality Improvement and Clinical Utility PrecivityAD Clinician Survey (QUIP I, ClinicalTrials.gov Identifier: NCT05477056) was a prospective, single‐arm cohort study among 366 patients evaluated by neurologists and other cognitive specialists. Participants underwent blood biomarker testing and received an amyloid probability score (APS), indicating the likelihood of a positive result on an amyloid positron emission tomography (PET) scan. The primary study outcomes were appropriateness of patient selection as well as result interpretation associated with PrecivityAD blood testing.Results: A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria. In the final analysis including these 347 patients (median age 75 years, 56% women), prespecified test result categories incorporated 133 (38%) low APS, 162 (47%) high APS, and 52 (15%) intermediate APS patients. Clinicians' pretest and posttest AD diagnosis probability changed from 58% to 23% in low APS patients and 71% to 89% in high APS patients (p < 0.0001). Anti‐AD drug therapy decreased by 46% in low APS patients (p < 0.0001) and increased by 57% in high APS patients (p < 0.0001).Interpretation: These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.

28 March 2023 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
IFIlana Fogelman
Ilana Fogelman
TWTim West
Tim West
JBJoel B. Braunstein
Joel B. Braunstein
PVPhilip B. Verghese
Philip B. Verghese
KKKristopher M. Kirmess
Kristopher M. Kirmess
KYKevin E Yarasheski
Kevin E Yarasheski
Background: The amyloid probability score (APS) is the model read‐out of the analytically validated mass spectrometry‐based PrecivityAD® blood test that incorporates the plasma Aβ42/40 ratio, ApoE proteotype, and age to identify the likelihood of brain amyloid plaques among cognitively impaired individuals being evaluated for Alzheimer's disease.Purpose: This study aimed to provide additional independent evidence that the pre‐established APS algorithm, along with its cutoff values, discriminates between amyloid positive and negative individuals.Methods: The diagnostic performance of the PrecivityAD test was analyzed in a cohort of 200 nonrandomly selected Australian Imaging, Biomarker & Lifestyle Flagship Study of Aging (AIBL) study participants, who were either cognitively impaired or healthy controls, and for whom a blood sample and amyloid PET imaging were available.Results: In a subset of the dataset aligned with the Intended Use population (patients aged 60 and older with CDR ≥0.5), the pre‐established APS algorithm predicted amyloid PET with a sensitivity of 84.9% (CI: 72.9–92.1%) and specificity of 96% (CI: 80.5–99.3%), exclusive of 13 individuals for whom the test was inconclusive.Interpretation: The study shows individuals with a high APS are more likely than those with a low APS to have abnormal amounts of amyloid plaques and be on an amyloid accumulation trajectory, a dynamic and evolving process characteristic of progressive AD pathology. Exploratory data suggest APS retains its diagnostic performance in healthy individuals, supporting further screening studies in the cognitively unimpaired.

8 February 2014 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
PMP. Mosali
P. Mosali
LBL. Bernard
L. Bernard
JWJ. Wajed
J. Wajed
ZMZ. Mohamed
Z. Mohamed
MEM. Ewang
M. Ewang
GHGeeta Hampson
Geeta Hampson

1 November 1990 in QJM: An International Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HGH. W. Gray
H. W. Gray
JMJ. H. Mckillop
J. H. Mckillop
RBR. G. Bessent
R. G. Bessent
IFI. Fogelman
I. Fogelman
MSM. L. Smith
M. L. Smith
FMF. Moran
F. Moran
A group of 78 patients with suspected pulmonary embolism was studied by both ventilation perfusion lung scanning and pulmonary angiography. Symptoms and clinical signs were analysed using Bayesian techniques to produce pre-test odds for pulmonary embolism in individual patients. While, as a group, those with embolism could be discriminated from those without on this basis, major overlap existed between the groups, invalidating the use of this approach for individual patients. Strict diagnostic criteria for interpretation of lung scans were accurated using pulmonary angiography as the ‘gold standard’, but at the expense of a significant number of patients (38 per cent) in the indeterminate (non-diagnostic) group. In the 48 patients in whom the test yielded a diagnostic result, there was a sensitivity of 100 per cent (15/15) and a specificity of 97 per cent (32/33). In the series as a whole, the likelihood of lung scanning correctly diagnosing pulmonary embolism was 55 per cent (15/27) and of correctly excluding embolism, 63 per cent (32/51). By the use of strict criteria for interpretation of lung scanning, reliable information can be obtained on the presence of absence of pulmonary embolism in a large proportion of patients suspected of having the condition. Such information is more discriminating than clinical signs and symptoms.

6 January 2005 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
Glen BlakeGlen Blake
Glen Blake
KKKaren M Knapp
Karen M Knapp
IFI. Fogelman
I. Fogelman